Description:
Thyroid cancer is the most prevalent endocrine malignancy, and the fifth most common cancer in women. Most cases have an excellent prognosis. However, some patients experience recurrence and develop metastases, while others present with highly aggressive disease, with poor prognosis and limited treatment options. The genomic framework of thyroid cancer has been largely elucidated, and most tumors have well-established genetic drivers. The identification of tumor-specific biomarkers has emerged as a critical diagnostic tool in the evaluation and clinical management of thyroid nodules. Recent FDA-approvals of highly selective kinase inhibitors for the treatment of advanced thyroid cancer underscore the essential role of molecular testing in guiding therapeutic choices. The scientific background, testing considerations, and clinical implications will be addressed in this presentation.
Learning Objectives:
- Describe the most common genetic alterations associated with the different types of primary thyroid cancer
- Identify the appropriate assays and platforms for molecular diagnostic testing of thyroid malignancies
- Discuss the role of genetic testing in the diagnostic assessment and management of thyroid nodules
- Recognize the clinical utility of molecular diagnostics in guiding systemic therapy selection for advanced disease
 |  |
|---|---|
| Speaker: Dora Dias-Santagata, PhD, FACMG Center for Integrated Diagnostics Massachusetts General Hospit | Moderator: Honey Reddi, PhD T&E Committee Genetics Subdivision Medical College of Wisconsin |
Level of Instruction: Basic
Date Recorded: January 28, 2021
Planned and coordinated by the Training and Education Committee
Continuing Education Credit Information
CME credit: 1.0CMLE credit: 1.0
Last day to claim credit: March 20, 2022
Accreditation Statements
AMA PRA Category 1 Credit(s)™
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.
The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
CMLE
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Note: Members of AMP can access this webinar at no cost. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
